文献速递骨肿瘤创伤骨科

在恶性肿瘤骨缺损患者中,采用游离血管化腓骨移植增强辐照自体骨能否在骨连接、功能与并发症率上达到与无骨缺损且未增强患者相当的水平,用于下肢节段性切除重建

Does Augmenting Irradiated Autografts With Free Vascularized Fibula Graft in Patients With Bone Loss From a Malignant Tumor Achieve Union, Function, and Complication Rate Comparably to Patients Without Bone Loss and Augmentation When Reconstructing Intercalary Resections in the Lower Extremity?
PubMed 文献 · Clin Orthop Relat Res · 2025-06-26

单中心回顾性研究比较了50例股骨或胫骨原发骨肉瘤节段切除患者,13例接受体外辐照自体骨联合游离血管化腓骨增强,37例仅用辐照自体骨。两组12个月骨连接比例无差异(p > 0.99),72个月移植骨丢失累积发生率无差异(亚分布HR 0.42,95%CI 0.10–1.84,p = 0.25),MSTS评分及并发症比例亦无差异。

要点

  • 增强组与单纯辐照自体骨组12个月骨连接比例无差异(p > 0.99)。
  • 72个月移植骨丢失累积发生率两组无差异(亚分布HR 0.42,95%CI 0.10–1.84,p = 0.25)。
  • 两组MSTS总分及各子项、并发症比例与并发症发生时间中位数均无差异。

核心结论

  • 在骨质量较差、缺损更复杂的病变中应用血管化腓骨增强辐照自体骨,其骨连接、移植骨存活、功能与并发症率与单纯辐照自体骨重建者无差异。

研究设计与样本

  • 单中心三级学术转诊中心回顾性病历审查,2002年1月至2023年4月由三名外科医生治疗345例股骨或胫骨骨肉瘤患者。
  • 345例中85例(25%)为原发骨肉瘤节段切除潜在合格者,排除23例(7%)采用其他重建技术、6例(2%)在24个月最低随访前死亡、3例(1%)未完成24个月随访、3例(1%)失访超过5年,最终50例(14%)纳入分析。
  • 50例中13例(26%)接受体外辐照自体骨联合血管化腓骨自体骨增强,37例接受单纯体外辐照骨重建。

主要发现

  • 单纯辐照自体骨组中5例在骨连接前发生移植骨丢失、1例在12个月前死亡,余31例中12个月内骨连接22例(71%)、延迟连接5例(16%)、骨不连4例(13%);增强组13例中12个月内骨连接9例,延迟连接与骨不连各2例;两组无差异(p > 0.99)。
  • 72个月移植骨丢失累积发生率单纯辐照自体骨组为32%(95%CI 19.1%–47.6%),增强组为13%(95%CI 2.3%–40.3%);72个月死亡累积发生率分别为25%(95%CI 13.9%–40.3%)与20%(95%CI 5.0%–48.6%)。
  • 以死亡为竞争事件的竞争风险回归显示两组移植骨丢失无差异(亚分布HR 0.42,95%CI 0.10–1.84,p = 0.25)。
  • MSTS评分中位数(范围)单纯辐照自体骨组为27(18–30),增强组为24(20–30),两组总分及各子项均无差异。
  • 单纯辐照自体骨组20例患者共发生28例次并发症,手术至并发症中位时间15个月(2–72);增强组7例患者共发生9例次并发症,中位时间18个月(1–23);两组并发症患者比例及并发症发生时间中位数无差异;4例发生供区相关问题,均未导致再次手术。

关键数值与推荐

  • 骨连接定义为两平面X线片上至少三个皮质出现骨桥接。
  • 12个月内无额外手术干预达到骨连接者为连接;超过12个月但在15个月前最终连接且无需额外干预者为延迟连接;15个月随访时整合不完全或愈合前需额外干预者为骨不连。
  • 移植骨存活定义为无任何程度丢失(部分或完全丢失归因于移植骨骨折、吸收或感染、复发后移除),采用竞争风险分析、以死亡为竞争事件,评估术后72个月。
  • 功能采用1993版肌肉骨骼肿瘤学会(MSTS)评分系统的六个子项评估。
  • 并发症定义为严重到需要手术的事件。

临床怎么用

  • 本研究中心在骨肉瘤切除后首选体外辐照自体骨重建;对影像学显示骨质量充足、皮质完整者选择单纯辐照自体骨,对肿瘤广泛破坏皮质但仍适合辐照后重建者,在辐照自体骨基础上加用血管化腓骨移植。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extracorporeally irradiated autografting is a recognized technique in reconstruction after intercalary resections, but it has drawbacks such as nonunion and graft fracture. Because sterilized autografts lose some of their mechanical properties due to involvement of the cortex with tumor, the curettage, and the adverse effects of irradiation or other sterilization techniques, some have proposed adding vascularized fibula to augment the autograft. Because this potentially adds morbidity, we sought to address the value of adding vascular fibular grafts to reconstruction with irradiated autografts. QUESTIONS/PURPOSES: Comparing patients who received an extracorporeally radiated autograft alone with those who received such a graft augmented by a free vascularized fibular autograft: (1) Was the proportion of patients who did not achieve union by 12 months higher in the group that received the augmented (vascularized) graft? (2) Did the augmented-graft group demonstrate greater survivorship free from graft loss at 72 months than did the group receiving an irradiated graft alone? (3) Were there between-group differences in functional results? (4) Were there between-group differences in complications, defined as those substantial enough to result in further surgery? METHODS: In our single-center study, conducted in a tertiary academic referral center, we performed a retrospective chart audit of patients undergoing intercalary resections for primary sarcomas of the femur and tibia. Between January 2002 and April 2023, three surgeons (HK, BK, DS) treated 345 patients for bone sarcoma of the femur or tibia. Of those, we considered 25% (85) treated with intercalary resection for primary bone sarcomas as potentially eligible. A further 7% (23 of 345) of patients were excluded because their reconstruction was performed using a technique other than irradiated autografts. Another 2% (6) had died prior to the minimum follow-up period of 24 months, another 1% (3) did not finish the 24-month follow-up, and 1% (3) were lost to follow-up for > 5 years, leaving 14% (50 of 345) for analysis here. Among these, 26% (13 of 50) of patients underwent reconstruction involving an extracorporeally irradiated autograft and augmentation with a vascularized fibula autograft. In the remaining 37 patients, reconstruction was performed using extracorporeally irradiated bone alone. During this period, intercalary resection was typically indicated for patients with primary bone sarcomas located in the metaphyseal or diaphyseal regions without articular involvement, provided that they demonstrated a favorable response to neoadjuvant therapy. In this predominantly young patient cohort, extracorporeally irradiated autografts were our preferred reconstruction method after sarcoma resection. Isolated extracorporeally irradiated autografts were selected for patients with radiologic evidence of adequate bone quality and preserved cortical integrity. In patients who have a tumor with extensive cortical destruction-yet still considered suitable for reconstruction after irradiation-vascularized fibular grafts were added to the irradiated autografts. In the group reconstructed with irradiated autograft alone, 54% (20 of 37) of patients were male and 46% (17) were female, with a median (range) age of 15 years (4 to 60). The diagnoses included osteosarcoma in 51% (19 of 37) of patients and Ewing sarcoma in 32% (12). The tumor was located in the tibia in 59% (22) of patients and in the femur in 41% (15). In the group receiving irradiated autograft augmented with vascularized fibula, 6 of the 13 patients were male and 7 were female, with a median (range) age of 13 years (6 to 40). Diagnoses included osteosarcoma in eight of 13 patients, Ewing sarcoma in four, and malignant mesenchymal tumor in one patient. Tumor originated from the femur in 11 patients and from the tibia in two. The two groups were similar in terms of histopathologic diagnosis, age, gender, follow-up duration, and tumor location within bone while the proportion of tumors originating from the femur was higher in the group treated with vascularized fibula augmentation (85% versus 41%; p < 0.05). Fixation technique and the ratio of the resected bone length to the entire bone were noted using the first postoperative radiograph. Bony union, defined as bony bridging in at least three cortices, was assessed using two-plane radiographs. Patients who achieved bony union within the first 12 months without undergoing any additional surgical intervention were classified as having union. Patients whose autograft incorporation exceeded 12 months but ultimately achieved union before 15 months without the need for additional intervention were classified as having delayed union. Nonunion was defined as when patients demonstrated incomplete integration at the 15-month follow-up or when patients needed additional intervention before healing. The survival of extracorporeally irradiated autografts, free from any degree of loss (partial or complete graft loss attributed to graft fracture resorption or graft removal after infection or recurrence), was assessed using competing risk analysis, with death as a competing event at 72 months postoperatively. Functional outcomes were measured using the 1993 version of the Musculoskeletal Tumor Society (MSTS) scoring system with its six subheadings. Complications were defined as events that were substantial enough to result in surgery. Problems related to fibular donor site were also recorded. RESULTS: In patients who received reconstruction with irradiated autografts alone, graft loss occurred in five patients before union was achieved, and one patient died before 12 months; thus, these patients were excluded from analysis on union within 12 months. Among the remaining 31 patients, union was achieved within 12 months in 71% (22) of patients, delayed union in 16% (5) of patients, and nonunion in 13% (4) of patients. In the group in which vascularized fibula was used to augment the irradiated autograft, union occurred within 12 months in 9 of 13 patients, while delayed union and nonunion were observed in two patients each. There was no difference between the groups (p > 0.99). At 72 months, the cumulative incidence of graft loss was 32% (95% confidence interval [CI] 19.1% to 47.6%) in the irradiated autograft-alone group and 13% (95% CI 2.3% to 40.3%) in the fibula-augmented group. The cumulative incidence of death at 72 months was 25% (95% CI 13.9% to 40.3%) in the irradiated autograft-alone group and 20% (95% CI 5.0% to 48.6%) in the fibula-augmented group. Competing risk regression for graft loss, treating death as a competing event, showed no difference between the groups (subdistribution HR 0.42 [95% CI 0.10 to 1.84]; p = 0.25). The median (range) MSTS score in patients reconstructed with irradiated autograft alone was 27 (18 to 30), while the median (range) MSTS score in those reconstructed with irradiated autograft augmented with vascularized fibula was 24 (20 to 30), and there were no differences between the groups in terms of total MSTS scores or any of the MSTS subdomains. In patients reconstructed with irradiated autograft alone, a total of 28 complications were observed in 20 patients. For those patients, the median (range) time from surgery to complication was 15 months (2 to 72). In patients reconstructed with irradiated autograft augmented with vascularized fibula, a total of nine complications were observed in seven patients. For those patients, the median (range) time from surgery to occurrence of complication was 18 months (1 to 23). There was no difference between the two groups in terms of the proportion of patients who faced complication or the median time to occurrence of complications. A total of four patients experienced donor site-related problems, none of which resulted in further surgery. CONCLUSION: Despite being applied in tougher lesions with less favorable bone quality, the addition of a vascularized fibula into extracorporeally irradiated autograft for reconstruction of intercalary resections yielded comparable outcomes in terms of bony union, graft survival, functional scores, and complications when compared with patients with more favorable host bone who received reconstruction with irradiated graft alone. Although our numbers were small, given the complexity and additional morbidity associated with vascularized fibular graft, its use might be reserved for selected patients in whom biological reconstruction is desired, but the host bone is deemed weakened and unlikely to be successful compared with those patients with more intact bone. Larger studies comparing this technique with other reconstruction options such as structural allografts, intercalary endoprostheses, or cement-rod constructs are needed to better define its role. We recommend reserving the use of vascularized fibula augmentation as a reinforcement strategy in reconstructions with irradiated autografts after intercalary resections of the femur and tibia, opting for it only when additional benefit is anticipated, given that it prolongs operative time, necessitates the involvement of a reconstructive surgery team, and introduces additional donor-site considerations. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Vahabi A, Kaya H, Kerekulov B, et al. Does Augmenting Irradiated Autografts With Free Vascularized Fibula Graft in Patients With Bone Loss From a Malignant Tumor Achieve Union, Function, and Complication Rate Comparably to Patients Without Bone Loss and Augmentation When Reconstructing Intercalary Resections in the Lower Extremity? Clin Orthop Relat Res. 2025. PMID: 40569278. doi:10.1097/CORR.0000000000003599

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。